Concepedia

Kevin M. Marks

KM

16

Publications

7.9K

Citations

15

H-Index

1999

Active since

Affiliations

Agios Pharmaceuticals (United States)(Current)

Harvard University

Massachusetts Institute of Technology

Massachusetts General Hospital

Stanford University

Kevin M. Marks is an author at Agios Pharmaceuticals (United States) specializing in medicine, tumor biology, and cancer research.

Top concepts

Publications per year

1999–2022

16

Publications

16

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

Lenny Dang, David W. White, Bryson D. Bennett et al. · Nature · 2009 · 4K citations · Full text

, , +4

Functional genomics reveal that the serine synthesis pathway is essential in breast cancer

Richard Possemato, Kevin M. Marks, Yoav D. Shaul et al. · Nature · 2011 · 1.7K citations · Full text

, , +9

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

Lenny Dang, David W. White, Bryson D. Bennett et al. · Nature · 2010 · 585 citations · Full text

, , +4

MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis

Katya Marjon, Michael J. Cameron, Phong Quang et al. · Cell Reports · 2016 · 415 citations · Full text

MAT2A Inhibition Blocks the Growth of MTAP-Deleted Cancer Cells by Reducing PRMT5-Dependent mRNA Splicing and Inducing DNA Damage

Peter Kalev, Marc L. Hyer, Zenon Konteatis et al. · Cancer Cell · 2021 · 214 citations

, , +9

Rows per page

1–5 of 16